Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 197 clinical trials
featured
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

refractory multiple myeloma who have received at least 3 but not more than 5 prior lines of multiple myeloma therapy.  

daratumumab
refractory multiple myeloma
  • 73 views
  • 28 May, 2020
  • 28 locations
featured
C1071003 MagnetisMM-3

The purpose of the study is to evaluate whether single-agent PF-06863135 can provide clinical benefit in participants with relapsed/refractory multiple myeloma. PF-06863135 is a bispecific

refractory multiple myeloma
  • 1 views
  • 17 Sep, 2021
  • 4 locations
Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

All patients with multiple myeloma (MM) are destined to relapse even with the best available approved agents. Median OS from diagnosis in the current era is reported at 5.4 years. Given that myeloma remains an incurable disease, future improved OS is therefore reliant on the expansion of salvage options for …

  • 22 views
  • 21 Jan, 2021
  • 1 location
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Primary Objectives: Part 1 (dose finding, experimental substudies): To determine or confirm the recommended dose of novel agents when combined with isatuximab with or without dexamethasone in participants with RRMM. Part 2 (expansion, experimental substudies): To demonstrate the clinical benefit of novel agents combined with isatuximab with or without dexamethasone …

  • 0 views
  • 14 Jun, 2021
  • 9 locations
A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

combination with lenalidomide and dexamethasone (KRd 27 mg/m2) in subjects with relapsed or refractory multiple myeloma (RRMM) with 1 to 3 prior lines of therapy.

  • 18 views
  • 03 Sep, 2021
  • 222 locations
Study of Early Relapsed Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

A Study Evaluating Treatment of Multiple Myeloma with Carfilzomib in Combination with Pomalidomide and Dexamethasone

  • 0 views
  • 26 Aug, 2021
  • 83 locations
AGENT-797 in Patients With Relapsed/Refractory Multiple Myeloma

This is a Phase I, open-label, dose-escalation, single arm study to explore the safety, tolerability, and preliminary clinical activity of agenT-797, an unmodified, allogeneic iNKT cell therapy, in subjects with relapsed/refractory MM, as well as define the RP2D.

  • 0 views
  • 14 May, 2021
  • 1 location
Dexamethasone Carfilzomib & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma

This phase I trial studies the side effects and best dose of wild-type reovirus (pelareorep) when given together with dexamethasone, carfilzomib, and nivolumab in treating patients with multiple myeloma that has come back (relapsed). Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of …

carfilzomib
ixazomib
monoclonal protein
immunoglobulin
hysterectomy
  • 21 views
  • 28 Jan, 2021
  • 2 locations
RAPA-201 T Cell Therapy for Relapsed Refractory Multiple Myeloma

RAPA-201-RRMM is an open-label, single-arm, non-randomized multicenter Phase II study of RAPA-201 autologous T cells in adults with relapsed, refractory multiple myeloma who have received at

  • 0 views
  • 04 Jul, 2021
  • 1 location
Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma

The purpose of this study is to evaluate the safety and tolerability of fluphenazine in patients with advanced multiple myeloma. The study will also describe the efficacy of this drug.

ejection fraction
proteasome inhibitor
thalidomide
progressive disease
measurable disease
  • 11 views
  • 07 Nov, 2020
  • 3 locations